LPCN 1154 · program
LPCN 1154 (oral brexanolone) for Postpartum depression
LPCN 1154 (BRLIZIO), oral brexanolone, for postpartum depression — Lipocine's lead CNS asset and the only indication it is being developed in. The concept is a 48-hour, self-administered, at-home oral course delivering the same active moiety as the approved IV brexanolone infusion (ZULRESSO) without the inpatient setting or continuous monitoring. Regulatory history is the defining feature of this program: FDA originally agreed a 505(b)(2) NDA could be filed on a single pivotal PK bridging study, which succeeded in June 2024 (bioequivalence to IV brexanolone met), with NDA submission targeted for Q4 2024 — then reversed course at a Q1 2025 meeting and required a target-population efficacy and safety study, announced 2025-02-06. Lipocine initiated the resulting pivotal Phase 3 on 2025-03-26 (NCT06979544, sponsor protocol LPCN 1154-24-002a, registered as 'LPCN 1154A'): a randomized, quadruple-blind, placebo-controlled outpatient trial in women aged 15-45 with severe postpartum depression across 18 US sites, 90 randomized, primary endpoint change from baseline in HAM-D17 total score at hour 60. Both scheduled DSMB reviews recommended continuing without modification. Topline on 2026-04-02: THE PRIMARY ENDPOINT WAS NOT MET (placebo-adjusted HAM-D17 difference -1.3 at hour 60, not statistically significant), although the drug separated from placebo at hour 12 (-3.9, p<0.01) and tolerability was strongly differentiated — no treatment-related serious or severe adverse events, no excessive sedation, no loss of consciousness, no treatment-related discontinuations, and no adverse event above 5% incidence. A post-hoc subgroup of 54 participants with a MINI-documented psychiatric history showed nominally significant separation at hours 12, 36 and 60 and day 30. On the strength of that post hoc analysis Lipocine has submitted breakthrough-therapy and fast-track designation requests (neither granted as of 2026-07-24), and as of the 2026-05-07 10-Q expects to submit a validation study protocol and request an FDA meeting while preserving capital and exploring partnering. The program is therefore recorded as active but at material risk, not discontinued.
Development timeline
- missedFull Phase 3 results presented as an oral presentation (Pharmaceutical Pipeline session) and a poster at the 2026 ASCP Annual Meeting, Miami, 26-29 May 2026 — the detailed efficacy, onset, durability-to-day-30 and safety dataset behind the April topline miss.↗
- missedPhase 3 topline in postpartum depression: LPCN 1154 MISSED its primary endpoint — no statistically significant reduction in HAM-D17 total score versus placebo at hour 60 (placebo-adjusted -1.3, N=90) — while showing early separation at hour 12 (-3.9, p<0.01) and a differentiated tolerability profile with no excessive sedation, no loss of consciousness and no treatment-related SAEs.↗
- Enrollment and participant dosing completed with 90 patients randomized (above the 80 planned). No drug discontinuations, excessive sedation, loss of consciousness or drug-related SAEs reported at that point. Last patient last visit followed on 2026-02-18, at which point Lipocine disclosed a mean baseline HAM-D of 28.3 and reported all nervous-system adverse events as mild to moderate. ClinicalTrials.gov records actual primary completion 2026-01-16 and actual study completion 2026-02-17.↗
- First patient dosed in the pivotal Phase 3 (NCT06979544), announced with topline guided to Q2 2026 and an NDA submission anticipated in mid-2026. Conducted at multiple US clinical sites in an outpatient setting with no requirement for healthcare-provider medical monitoring. Enrollment tracked publicly thereafter: one third randomized at 2025-09-30, first DSMB review of 30 completers recommended continuing without modification (2025-11-18, 47 dosed, no discontinuations, dose reductions, drug-related SAEs, excessive sedation or loss of consciousness), 66 of a planned 80 randomized at 2025-12-15, second DSMB review of 82 randomized/74 dosed recommending continuation and screening closed (2026-01-12).↗
- Lipocine announced initiation of the outpatient pivotal Phase 3 safety and efficacy trial of LPCN 1154 in PPD, with first patient dosing expected in Q2 2025. Two-arm randomized, blinded, placebo-controlled design in women aged 15 and older with severe PPD; 48-hour dosing period; primary endpoint change from baseline in HAM-D; secondary endpoints MADRS and HAM-A; trial size powered on the treatment effect observed with approved injectable brexanolone. Per FDA protocol feedback, patients self-administer at home. This date is used as last_phase_change; the ClinicalTrials.gov actual start date is 2025-06-16.↗
- REGULATORY REVERSAL — the pivotal turning point of the program. Following a Q1 2025 meeting to discuss the NDA submission package, FDA advised Lipocine that, in addition to the completed PK dosing-regimen confirmation data, an efficacy and safety study of oral LPCN 1154 in the target population would be required for the 505(b)(2) NDA. The planned Q4 2024 NDA filing did not proceed and Lipocine began planning a Phase 3. No event row was written for this because the closed event vocabulary has no code for an adverse FDA meeting outcome or changed regulatory guidance (fda_crl and fda_clinical_hold both misdescribe it) — reported as a vocabulary gap.↗
- Pivotal PK bridging study met all standard bioequivalence criteria against commercial IV brexanolone (open-label randomized crossover, 24 healthy postmenopausal women, versus the approved IV90 high-dose infusion regimen): Cmax GMR 105% (90% CI 92-120%), AUC0-inf 97% (88-107%), AUC0-t 88% (80-99%), Ctrough criterion met with a higher geometric mean trough than IV. At this point FDA had agreed a 505(b)(2) NDA could be supported by the PK bridge alone and Lipocine targeted NDA submission by end of Q4 2024. Treatment was well tolerated with no sedation or somnolence events.↗
Readouts
- 2026-05-26ReportedFull resultsmissedNCT06979544
Full Phase 3 results presented as an oral presentation (Pharmaceutical Pipeline session) and a poster at the 2026 ASCP Annual Meeting, Miami, 26-29 May 2026 — the detailed efficacy, onset, durability-to-day-30 and safety dataset behind the April topline miss. ↗
- 2026-04-02ReportedTopline datamissedNCT06979544
Phase 3 topline in postpartum depression: LPCN 1154 MISSED its primary endpoint — no statistically significant reduction in HAM-D17 total score versus placebo at hour 60 (placebo-adjusted -1.3, N=90) — while showing early separation at hour 12 (-3.9, p<0.01) and a differentiated tolerability profile with no excessive sedation, no loss of consciousness and no treatment-related SAEs. ↗
Clinical trials in Postpartum depression
NCT06979544LPCN 1154-24-002aPhase 3Completedn=90
A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
mixedsecondaryHAM-D17 total score, change from baseline at hours 12 and 36 and days 7 and 30 (full analysis set) — Placebo-adjusted differences: hour 12 -3.9; hour 36 -1.7; day 7 -1.2; day 30 -2.3 (hour 12 p<0.01 (nominal); hours 36, day 7 and day 30 not statistically significant)
Rapid early separation that did not hold. LPCN 1154 separated from placebo at hour 12 (-3.9, p<0.01), consistent with the rapid-onset hypothesis, but the difference narrowed at hour 36 and was not significant at any timepoint from hour 36 onward. Because the primary endpoint at hour 60 failed, all of these p-values are nominal.
missedprimaryHAM-D17 total score, change from baseline to hour 60 (full analysis set) — Placebo-adjusted difference -1.3 (MMRM least-squares means), N=90 (not statistically significant)
PRIMARY ENDPOINT NOT MET. Oral LPCN 1154 did not significantly reduce HAM-D17 total score versus placebo at hour 60 in the full Phase 3 analysis set of 90 women with severe postpartum depression (mean baseline HAM-D 28.3). This was the only pre-specified, alpha-protected comparison in the study.
mixedexploratoryHAM-D17 total score, change from baseline — POST HOC subgroup with a MINI-documented history of psychiatric conditions (n=54) — Placebo-adjusted differences: hour 12 -7.2; hour 36 -5.0; hour 60 -6.1; day 7 -4.2; day 30 -5.3 (hour 12 p<0.001; hour 36 p<0.05; hour 60 p<0.01; day 30 p<0.05 — ALL NOMINAL; day 7 not statistically significant)
POST HOC, NOT PRE-SPECIFIED. Among the 54 of 90 participants with a psychiatric history diagnosed via the Mini-International Neuropsychiatric Interview, LPCN 1154 showed larger separations that reached nominal significance at hours 12, 36 and 60 and at day 30. The subgroup was defined after unblinding, all p-values are nominal with no multiplicity control, and day 7 did not separate. Lipocine used this analysis to request breakthrough-therapy and fast-track designations and to justify a possible validation study; it is hypothesis-generating only.
metsafetySafety and tolerability (adverse events, serious adverse events, sedation)
The clearly positive part of the readout. No treatment-related severe or serious adverse events; no cases of excessive sedation or loss of consciousness anywhere in the LPCN 1154 development programme; no treatment-related discontinuations; and no adverse event, including somnolence or dizziness, occurring in more than 5% of LPCN 1154-treated participants. All reported nervous-system adverse events were mild to moderate. Lipocine's position is that this profile supports fully outpatient, at-home administration without healthcare-provider monitoring — the central differentiation versus the approved IV brexanolone infusion, which requires continuous monitored administration.
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| LPCN 1154 (BRLIZIO) oral tablet — 48-hour at-home courseLipocine lipidic oral delivery platform (lipid-based composition forming a dispersed phase in the GI tract to solubilize and improve absorption of poorly soluble drugs) Oral tablets self-administered over a 48-hour treatment period in an outpatient/at-home setting, with no requirement for healthcare-provider monitoring (design agreed with FDA). The regimen was fixed by a 2024-02-06 single-arm dosing-regimen confirmation study (n=8) using the scaled-up 'to be marketed' formulation, then validated on 2024-06-25 against commercial IV brexanolone (open-label randomized crossover, 24 healthy postmenopausal women) versus the approved 60-hour IV90 high-dose infusion regimen: Cmax GMR 105% (90% CI 92-120%), AUC0-inf 97% (88-107%), AUC0-t 88% (80-99%), all within standard bioequivalence bounds, with the Ctrough criterion met at a higher geometric mean trough than IV. The mg strength and the number of individual doses inside the 48-hour course have never been publicly disclosed in any Lipocine press release, 8-K or 10-Q, and ClinicalTrials.gov gives only 'Oral LPCN 1154A tablets for 48 hours' — so no numeric dose is stated here. | Oral | Few doses | — |
Mechanism of action
Brexanolone is bioidentical to allopregnanolone, an endogenous neuroactive steroid metabolite of progesterone that acts as a positive allosteric modulator of GABA-A receptors, potentiating GABA-evoked chloride current at both synaptic and extrasynaptic receptor populations at a steroid site distinct from the benzodiazepine site. The therapeutic rationale in postpartum depression is that the abrupt fall in allopregnanolone after delivery leaves GABA-A signalling transiently dysregulated, and restoring exposure produces antidepressant effect within hours rather than weeks. LPCN 1154 does not alter this mechanism — it is the same molecule delivered orally via Lipocine's lipidic solubilization platform, so the pharmacology is brexanolone's and the differentiation is entirely in route, setting and exposure profile: a 48-hour self-administered oral course rather than a 60-hour monitored IV infusion. The FDA-approved IV label states that the precise mechanism by which brexanolone exerts its antidepressant effect is not fully understood, and the exact relationship between GABA-A modulation and clinical antidepressant response remains unestablished. Notably, the Phase 3 oral programme reported no cases of excessive sedation or loss of consciousness across the full development experience, in contrast to the sedation risk that drives the IV product's REMS.
| Target | Action | Affinity |
|---|---|---|
| GABA-A receptorprimary | PAM | —ⓘ |
← Full LPCN 1154 compound page (identity, identifiers, all indications)
Sources
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression — 90 randomized (8-K Exhibit 99.1, 2026-01-20) — Lipocine Inc. via SEC EDGAR
- Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression (8-K Exhibit 99.1, 2025-06-26) — Lipocine Inc. via SEC EDGAR
- Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 (8-K Exhibit 99.1, 2025-03-26) — Lipocine Inc. via SEC EDGAR
- Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study (2024-06-25) — Lipocine Inc. (via PR Newswire)
- Lipocine Receives Updated Regulatory Guidance on LPCN 1154 (8-K Exhibit 99.1, 2025-02-06) — FDA requires a target-population efficacy and safety study for the 505(b)(2) NDA — Lipocine Inc. via SEC EDGAR
- Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression (8-K Exhibit 99.1, 2026-04-02) — Lipocine Inc. via SEC EDGAR
- NCT06979544 (LPCN 1154-24-002a) — A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression — ClinicalTrials.gov (U.S. National Library of Medicine)
- Novel oral rapid-acting neuroactive steroid for treatment of postpartum depression: a placebo-controlled Phase 3 clinical trial of LPCN 1154A — 2026 ASCP Annual Meeting (oral presentation; companion poster session W98) — American Society of Clinical Psychopharmacology (via CNS Pulse)
- ZULRESSO (brexanolone) injection, for intravenous use, CIV — FDA prescribing information (mechanism of action: neuroactive steroid GABA-A receptor positive modulator) — Sage Therapeutics, Inc. via DailyMed (U.S. National Library of Medicine)